While gene activation by specific transcription factors is important during development, coordinated repression is also an essential process ([@bib6]). Gene silencing represents an effective method to ensure that genes and transposons are not inappropriately activated. Gene repression can be carried out on a regional basis to inactivate large blocks of the genome by the formation of heterochromatin ([@bib27]). Heterochromatization relies on the dense, higher-order packing of nucleosomes, which compete for DNA binding with transcription factors ([@bib42]; [@bib47]; [@bib56]). Once heterochromatin forms, it is maintained by a set of largely conserved proteins.

In *Drosophila*, heterochromatin formation occurs early during embryogenesis, where it is targeted to large blocks of repetitive DNA sequences ([@bib27]), including both mobile transposons and immobile mutated derivatives ([@bib85]). Active suppression through condensation into heterochromatin prevents the mobilization of transposons. Nevertheless, some regulated transcription of heterochromatic sequences is required for normal cellular functions. For example, the telomeres of *Drosophila* are maintained by the transcription and transposition of mobile elements from heterochromatic sites ([@bib58]), and actively expressed histone and ribosomal RNA genes are located within heterochromatic regions ([@bib91]). Thus, heterochromatin serves many distinct functions and must be tightly regulated to coordinate gene expression.

The spreading of heterochromatin results in an interesting phenotype in *Drosophila*, whereby genes near a heterochromatin--euchromatin boundary may become repressed ([@bib27]). For example, when *white*^*+*^ (*w^+^*) transgenes are located at such a boundary, the eye can have a mottled appearance where some ommatidia express pigment while others do not. This phenomenon is known as position-effect variegation (PEV). Mutations that suppress PEV {*i.e.*, suppressors of variegation \[*Su(var)*\]} identify genes that promote heterochromatin formation. Indeed, many of the genes required for heterochromatin function were identified in PEV modifier screens ([@bib74]; [@bib26]; [@bib9]). Reducing heterochromatization by *Su(var)* mutations results in derepression of gene expression at the edges of heterochromatin blocks, suggesting that the boundaries between repressed and active chromatin expand and contract ([@bib73]; [@bib89]). For example, the highly conserved Heterochromatin Protein 1a (HP1a), encoded by *[Su(var)](http://flybase.org/reports/FBgn0003607)205*, is critical for heterochromatin formation and function ([@bib25]); mutants show strong suppression of variegation ([@bib38]; [@bib26]; [@bib17]). Similarly, HP1a is also required to repress the expression of transposons ([@bib85]). HP1a may also be required for preventing the misexpression of large cohorts of genes, such as those normally expressed in specialized cell types ([@bib34]; [@bib30]). Indicative of its central role in heterochromatization, HP1a associates with newly formed heterochromatin in the *Drosophila* embryo and is thought to be found in all cells throughout the life of the animal ([@bib39]).

Both the formation and relaxation of heterochromatin depend primarily on histone modifications. Heterochromatin is thought to be nucleated by HP1a binding to di- and trimethylated Histone 3 Lys9 (H3K9me) and spread by multimerization of HP1a over blocks of chromatin ([@bib65]; [@bib12]). In *Drosophila*, the methyltransferases Eggless (Egg)/SETDB1 and Su(var)3--9 catalyze the addition of methyl groups at H3K9 ([@bib18]; [@bib93]), but there may be additional ways to bind HP1a to chromatin. Work in *Drosophila* shows that destruction of the H3K9me site recognized by HP1a (via a K9 to R9 mutation) reduces, but does not abolish, HP1a binding and heterochromatin formation ([@bib70]). Moreover, HP1a binding does not always occur in regions with high H3K9me or methyltransferase activity ([@bib30]). These findings raise the possibility that HP1a may bind to chromatin independently of H3K9me.

Originally described over 40 years ago ([@bib62]), the *small ovary* (*sov*) locus is associated with a range of mutant phenotypes including disorganized ovarioles, egg chamber fusions, undifferentiated tumors, and ovarian degeneration ([@bib88]). In the present work, we define the molecular identity and function of Sov. We demonstrate that *sov* encodes an unusually long C~2~H~2~ zinc-finger (ZnF) nuclear protein. Interestingly, Sov is in a complex with HP1a ([@bib1]), suggesting that it could be important for heterochromatin function. Indeed, we find that loss-of-function *sov* mutations result in strong dominant suppression of PEV in the eye, similar to HP1a ([@bib27]). Moreover, we show that Sov and HP1a colocalize in the interphase nucleus in blastoderm embryos. Additionally, our RNA-sequencing (RNA-Seq) analysis indicates that *sov* activity is required in the ovary to repress the expression of large gene batteries that are normally expressed in nonovarian tissues. We further demonstrate that Sov represses transposons, including those that are required for telomere maintenance. Collectively, these data indicate that Sov is a novel repressor of gene expression involved in many, if not all, of the major functions of HP1a in heterochromatization.

Materials and Methods {#s1}
=====================

We have adopted the FlyBase-recommended resources table, which includes all genetic, biological, cell biology, genomics, manufactured reagents, and algorithmic resources used in this study (Supplemental Material, Table S1).

Flies and genetics {#s2}
------------------

The *sov* locus was defined by three *X*-linked, female-sterile mutations including *sov^2^*, which was mapped to ∼19 cM ([@bib62]; [@bib63]) and refined to cytological region 6BD ([@bib88]). We used existing and four custom-made deletions (*Df(1)BSC276*, *BSC285*, *BSC286*, and *BSC297*) to map *sov* to the four-gene *[CG14438--shf](http://flybase.org/reports/FBgn0286831)* interval ([Figure 1](#fig1){ref-type="fig"}). *sov* mutations complemented *shf*^*2*^, but not *P{SUPor-P}CG14438^KG00226^* or *P{GawB}NP6070*, suggesting that [*CG14438*](https://identifiers.org/bioentitylink/FB:FBgn0029899?doi=10.1534/genetics.119.302590) or *CR43496* was *sov*, which we confirmed by generating *Df(1)sov* (*X*:6756569..6756668;6770708) from FLP recombination between *P{XP}CG14438^d07849^* and *PBac{RB}e03842* ([@bib68]; [@bib20]) to remove only those two genes.

![*sov* is [*CG14438*](https://identifiers.org/bioentitylink/FB:FBgn0029899?doi=10.1534/genetics.119.302590). (A) Genes of the genomic interval *X*:6710000--6810000 ([@bib32]). (B) Deficiency (*Df*) and Duplication (*Dp*) mapping. Noncomplementing (*sov*^--^, red) and complementing (*sov^+^*, green) alleles, and rearrangements, are shown. (C) Schematic of the [*CG14438*](https://identifiers.org/bioentitylink/FB:FBgn0029899?doi=10.1534/genetics.119.302590) (black) and *CR43496* (purple) genes. Transcription start sites (bent arrows), introns (thin lines), noncoding regions (medium lines), and coding regions (thick lines) are shown. Transposon insertions (red triangles), GFP tag insertion in rescuing transgene (green triangle), point mutations (red lines), the region targeted by the short hairpin RNA interference transgene (base-paired), and Sov protein features are shown. ChrX, *X* chromosome; NLS, nuclear localization sequence.](877f1){#fig1}

We used the dominant female-sterile technique for germline clones ([@bib15]). Because [*ovo*](https://identifiers.org/bioentitylink/FB:FBgn0003028?doi=10.1534/genetics.119.302590)^*D1*^ egg chambers do not support development to vitellogenic stages of oogenesis, we scored for the presence of vitellogenic eggs in *sov* mutant germline clones. Test chromosomes that were free of linked lethal mutations by male viability (*sov^2^)* or rescue by *Dp(1;3)DC486* \[*sov^EA42^* and *Df(1)sov*\] were recombined with *P{ry^+t7.2^ = neoFRT}19A*, and verified by complementation tests and PCR. We confirmed *P{ry^+t7.2^ = neoFRT}19A* functionality by crossing to *P{w^+mC^ = GMR-hid}SS1*, *y^1^ w\* P{ry^+t7.2^ = neoFRT}19A*; *P{w^+m\*^=GAL4-ey.H}SS5*, *P{w^+mC^ = UAS-FLP.D}JD2* and scoring for large eye size. We crossed females with FRT chromosomes to *P{w^+mC^ = ovoD1-18}P4.1*, *P{ry^+t7.2^ = hsFLP}12*, *y^1^ w^1118^ sn^3^ P{ry^+t7.2^ = neoFRT}19A/Y* males for 24 hr of egg laying at 25°. We heat shocked for 1 hr at 37° on days 2 and 3. We dissected females (5 days posteclosion) to score for *ovo^D1^* or vitellogenic morphology.

We generated a *PBac*{*GFP-sov}* transgene sufficient to rescue the *sov* mutant phenotype. The encoded N-terminal fusion protein uses the Sov initiation codon, followed immediately by a multitag sequence \[3xFLAG, Tobacco Etch Virus (TEV) protease site, streptavidin tag II (StrepII), superfolder GFP (sfGFP), fluorescein arsenical helix binder (FLAsH) tetracysteine tag, and flexible 4xGlyGlySer (GGS) linker\] and the full Sov coding sequence. The transgene contains 3040 nt of regulatory sequences upstream of the distal transcriptional start site of *sov* and 2692 nt downstream of the 3′ untranslated region. See the supplement for FASTA files of the genomic and complementary DNA *GFP-sov* sequences. The *GFP-sov* construct derives from P\[acman\] BAC clone CH322-191E24 (X:6753282--6773405) ([@bib83]) grown in the SW102 strain ([@bib87]). In step one of the construction, we integrated the positive/negative marker CP6-RpsL/Kan (CP6 promoter with a bicistronic cassette encoding the RpsL followed by the Kan), PCR-amplified with primers N-CG14438-CP6-RN-F and -R between the first two codons of *sov*, and selected (15 μg/ml Kanamycin). We integrated at the galK operon in DH10B bacteria using mini-λ-mediated recombineering ([@bib21]). We amplified DH10B::CP6-RpsL/Kan DNA using primers N-CG14438-CP6-RN-F and -R. Correct events were identified by PCR, as well as resistance (15 µg/ml kanamycin) and sensitivity (250 µg/ml streptomycin). In step two, we replaced the selection markers with a multitag sequence ([@bib84]), tailored for N-terminal tagging (N-tag) and counterselected (250 µg/ml streptomycin). The N-tag (3xFLAG, TEV protease site, StrepII, superfolder GFP, FLAsH tetracysteine tag, and flexible 4xGlyGlySer (GGS) linker) was *Drosophila* codon optimized in an R6Kγ plasmid. We transformed the plasmid into EPI300 for copy number amplification. We confirmed correct events by PCR and Sanger DNA sequencing. Tagged P\[acman\] BAC clone DNA was injected into *y^1^ M{vas-int.Dm}ZH-2A w\**; *PBac{y+-attP-3B}VK00033* embryos, resulting in *w^1118^*; *PBac{y^+mDint2^ w^+mC^ = GFP-sov}VK00033*. All strains were maintained using standard laboratory conditions.

Western blotting {#s3}
----------------

We dissected ovaries from 10 well-fed 0--2-day-old females into PBS and lysed them in 300 μl 0.1% PBST (PBS + 0.1% Tween 20), 80 μl of 5 × SDS loading dye was added to the total protein extract, and the samples were boiled at 95° for 10 min. Next, 30 μl of extract per sample was loaded into a commercial 7.5% polyacrylamide gel and run until the large bands of a high-molecular weight protein standard ladder were fully separated. Gels were blotted onto a 0.2-μm nitrocellulose membrane by the wet transfer method, using Tris/glycine transfer buffer containing 0.02% SDS and 10% MeOH under 150 mA for 3 hr. Primary antibodies used were: rabbit anti-GFP (1:2000, A11122; Fisher Scientific, Pittsburgh, PA), mouse anti-FLAG (1:5000, F1804; Sigma \[Sigma Chemical\], St. Louis, MO), and mouse anti-β-Tubulin \[1:1000, Developmental Studies Hybridoma Bank (DSHB) E7\]. Secondary antibodies used were: HRP-conjugated goat anti-mouse (1:5000, 31430; Fisher Scientific) and HRP-conjugated goat anti-rabbit (1:5000, 31460; Fisher Scientific).

Microscopy {#s4}
----------

We fixed ovaries in 4 or 5% EM-grade paraformaldehyde in PBS containing 0.1 or 0.3% Triton X-100 (PBTX) for 10--15 min, washed 3 × 15 min in PBTX, and blocked for \> 30 min in 2% normal goat serum, and 0.5--1% bovine serum albumin in PBS with 0.1% Tween 20 or 0.1% Triton X-100. Antibodies and DAPI were diluted into blocking buffer. We incubated in primary antibodies overnight at 4° and secondaries for 2--3 hr at room temperature. The following primary antibodies were used: rabbit anti-Vasa (1:10,000, gift from Ruth Lehmann), rat anti-Vasa (1:10, DSHB), mouse anti-αSpectrin (αSpec; 1:200, DSHB), mouse anti-Orb (1:10, DSHB orb 4H8), guinea pig anti-Traffic jam (Tj) (1:1500, gift from Mark Van Doren, ([@bib41]), mouse anti-GFP (1:200, DSHB DSHB-GFP-4C9), and rabbit anti-GFP (1:700--1:1000, A11122; Fisher Scientific). Secondary antibodies and stains used were: Alexa-fluor 488, 568, or 647 goat anti-mouse, goat anti-rat, goat anti-guinea pig, and goat anti-rabbit (1:500; Molecular Probes, Eugene, OR), DAPI (1:1000, D1306; Invitrogen, Carlsbad, CA), phalloidin (1:500, A12380; Invitrogen), and Alexa-fluor 633-conjugated wheat germ agglutinin (WGA) (1:1000, W21404; Fisher Scientific).

Embryos (1--2 hr) were prepared for live imaging in halocarbon oil ([@bib52]). We imaged ovaries and embryos using a Nikon (Garden City, NY) Ti-E system, or Zeiss (\[Carl Zeiss\], Thornwood, NY) LSM 780 microscope and eyes with a Nikon SMZ.

Image analysis {#s5}
--------------

In this study, tumors were defined as cysts enveloped by follicle cells containing at least six spectrosome dots, as indicated by αSpec immunostaining. Egg chamber fusion events were defined as a single cyst enveloped by a monolayer of follicle cells containing \> 15 nurse cells and \> 1 oocyte, but no spectrosome dots. Germaria were counted from randomly sampled dispersed ovarioles isolated from ≥ 10 individual females and replicated in at least two independent experiments; representative data from a single experiment are reported in the text.

Images were assembled using ImageJ (National Institutes of Health) and Photoshop (Adobe) software to crop regions of interest, adjust brightness and contrast, separate or merge channels, and generate maximum-intensity projections as noted.

For image intensity quantification of nuclear staining in embryos, line scans were converted to a --3- to 3-μm scale such that the 0.0 position marked the peak HP1a fluorescence intensity. The fluorescence intensities of red fluorescent protein (RFP)-HP1a and GFP-Sov were individually normalized to set their respective maxima to 100.

DNA-Seq {#s6}
-------

Genomic DNA was extracted from 30 whole flies per genotype ([@bib37]); ([@bib77]) to prepare DNA-sequencing (DNA-Seq) libraries (Nextera DNA Library Preparation Kit). We used 50-bp, single-end sequencing (Illumina HiSeq 2500, CASAVA base calling). Sequence data are available at the Sequence Read Archive (SRA) (SRP14438). We mapped DNA-Seq reads to the FlyBase r6.16 genome with Hisat2 (--k 1 --no-spliced-alignment)([@bib46]). We used mpileup and bcftools commands from SAMtools within the genomic region *X*:6756000--6771000 ([@bib54]; [@bib53]) for variant calling and SnpEff to determine the nature of variants in *sov* mutants ([@bib16]).

RNA-Seq {#s7}
-------

Stranded PolyA+ RNA-Seq libraries from *sov* (maternal allele listed first: *sov^EA42^*/*sov^2^*, *sov^ML150^*/*sov^2^*, *Df(1)sov*/*sov^2^*, *c587-GAL4 \> sov^RNAi^*, *tj-GAL4 \> sov^RNAi^*, *da-GAL4 \> sov^RNAi^*, *nos-GAL4 \> sov^RNAi^*) and control ovaries (maternal allele listed first: *sov^EA42^*/*w^1118^*, *sov^ML150^*/*w^1118^*, *Df(1)sov*/*w^1118^*, *sov^2^/w^1118^*, *w^1118^/sov^2^*, *w^1118^/w^1118^*, *c587-GAL4 \> mCherry^RNAi^*, tj*-GAL4 \> mCherry^RNAi^*, *da-GAL4 \> mCherry^RNAi^*, *nos-GAL4 \> mCherry^RNAi^*) were created using a standard laboratory protocol ([@bib51]) and are available at the Gene Expression Omnibus (GEO) (GSE113977). We collected only ovaries containing distinguishable germaria and/or egg chambers for these experiments. We extracted total RNA (RNeasy Mini Kit, QIAGEN, Valencia, CA) in biological triplicates from 15 ovaries (4--5 days posteclosion) and used 200 ng with 10 pg of External RNA Controls Consortium (ERCC) spike-in control RNAs (pools 78A or 78B) for libraries ([@bib43]; [@bib96]; [@bib50]; [@bib71]). We used 50-bp, single-end sequencing as above. Tissue expression analyses are from GEO accession GSE99574 ([@bib90]), a resource for comparing gene expression patterns.

We mapped RNA-Seq reads to FlyBase r6.21 with Hisat2 (--k 1 --rna-strandness R --dta) ([@bib46]). We determined read counts for each attribute of the FlyBase r6.21 GTF file (with ERCC and transposable element sequences) with HTSeq-count ([@bib2]). Transposon sequences were from the University of California Santa Cruz (UCSC) Genome Browser RepeatMasker track (Smit *et al.* 2013--2015; [@bib13]).

We conducted differential expression analysis with DESeq2 (pAdjustMethod = "fdr") ([@bib57]). We removed genes with read counts less than one and read counts for transposable elements with more than one location were summed for the DESeq2 analysis. *Df(1)sov/sov^2^* replicate 3 and *sov^2^/w^1118^* replicate 1 failed. For *sov* mutant *vs.* control DESeq2 analysis, all *sov* mutants were compared to all wild-type controls. For tissue types, we compared each sexed tissue to each sexed whole organism. We used reads per kilobase per million reads for gene-level expression. FlyBase identifiers of genes found to be expressed according to either "high" or "very high" levels in 0--2-hr-old embryos according to [@bib33] were batch downloaded from flybase.org RNA-Seq profiles (Table S3). Raw read FASTA files of RNA-Seq data for HP1a, SETDB1, and WDE germline knockdown ([@bib97]; GSE109850) were downloaded from the SRA (SRP131778) and analyzed according to the above parameters.

For heatmaps, we calculated Euclidean distance and performed hierarchical cluster analysis (agglomeration method = Ward) on the respective columns. The rows for gene and tissue heatmaps were *k*-means clustered (*k* = 5 for gene and *k* = 7 for tissue heatmaps), and values were mean-subtracted scaled across genotypes. The rows for the transposon heatmap were ordered according to element and values were mean-subtracted scaled across genotypes.

For read density tracks, replicate raw read files were combined. Bedgraph files were created with bedtools genomecov ([@bib72]) visualized on the UCSC genome browser ([@bib45]). Tracks were scaled by the number of reads divided by total reads per million.

We used PANTHER to perform gene ontology (GO) term enrichment analysis ([@bib3]; [@bib61]; [@bib82]). We report significantly enriched GO terms as above but with the PANTHER GO-Slim Biological Process annotation data set ([Table 3](#t3){ref-type="table"}).

Statistical analysis {#s8}
--------------------

Data were plotted and statistical analysis was performed (Microsoft Excel and GraphPad Prism). Data were subjected to the D'Agnostino and Pearson normality test, followed by a Student's two-tailed *t*-test or a Mann--Whitney *U*-test. We used Fisher's exact test and Bonferroni correction on the GO biological process complete annotation data set.

Data availability {#s9}
-----------------

Strains and plasmids, and their sources, are detailed in Table S1. All sequencing data are available at public repositories: DNA-Seq data are available at the SRA (SRP14438) and RNA-Seq data are available at the GEO (GSE113977 and GSE99574). Supplementary tables are available at Figshare: Table S1, FlyBase ART file contains all experimental materials used in the study; Table S2, Differentially expressed genes in *sov* mutants *vs.* controls; Table S3, gene list of high or very high levels in 0--2-hr-old embryos according to [@bib33]); and Table S4, common and differentially expressed genes following germline knockdown of *sov* *vs.* HP1a, SETDB1, and WDE. A supplementary text file includes FASTA sequences for the *GFP-sov* transgene. Supplemental material available at Figshare: <https://figshare.com/articles/Genetics_09_13_2019/9828002>.

Results {#s10}
=======

The essential gene *small ovary* corresponds to *CG14438* {#s11}
---------------------------------------------------------

To refine the previous mapping of *sov* ([@bib62]; [@bib63]; [@bib88]), we complementation tested *sov* mutations with preexisting and custom-generated deficiencies, duplications, and transposon insertions ([Figure 1, A and B](#fig1){ref-type="fig"}). Both female-sterile and lethal *sov* alleles mapped to the two-gene deletion *Df(1)sov*, showing that *sov* corresponds to either the protein-coding [*CG14438*](https://identifiers.org/bioentitylink/FB:FBgn0029899?doi=10.1534/genetics.119.302590) gene or the intronic, noncoding *CR43496* gene. Rescue of female sterility and/or lethality of *sov^2^*, *sov^EA42^*, and *Df(1)sov* with *Dp(1;3)sn^13a1^*, *Dp(1;3)DC486*, and *PBac{GFP-sov}* (*GFP-sov*) confirmed our mapping and did not replicate previous duplication-rescue results, suggesting that *sov^EA42^* disrupts adjacent female-sterile and lethal loci ([Table 1](#t1){ref-type="table"}) ([@bib88]). We conclude that female sterility and lethality map to the same location.

###### Complementation of *sov* alleles

                      *sov^NP6070^*   *sov^KG00226^*   *sov^ML150^*   *sov^EA42^*   *sov^2^*   *Df(1)sov*
  ------------------- --------------- ---------------- -------------- ------------- ---------- ------------
  *sov^NP6070^*       Fs              Fertile          Fs             Fs            Fertile    Fs
  *sov^KG00226^*      Fertile         Fertile          Fs             Fs            Fertile    Fs
  *sov^ML150^*        Lethal          Lethal           Lethal         Lethal        Lethal     Lethal
  *sov^EA42^*         Lethal          Lethal           Lethal         Lethal        Lethal     Lethal
  *sov^2^*            Fertile         Fertile          Fs             Fs            Fs         Fs
  *Df(1)sov*          Lethal          Lethal           Lethal         Lethal        Lethal     Lethal
  *GFP-sov^+^*        N.D.            N.D.             N.D.           Rescue        Rescue     Rescue
  *Dp(1;3)DC486*      N.D.            N.D.             N.D.           Rescue        Rescue     Rescue
  *Dp(1;3)sn^13A1^*   N.D.            N.D.             Rescue         Rescue        Rescue     Rescue

Maternally contributed chromosome listed on top. Fs denotes female sterile. Fertile denotes female fertility. N.D. denotes no data.

To further map *sov*, we sequenced [*CG14438*](https://identifiers.org/bioentitylink/FB:FBgn0029899?doi=10.1534/genetics.119.302590) and *CR43496* to determine if DNA lesions in these genes exist on the chromosomes carrying *sov* mutations. While *CR43496* contained three polymorphisms relative to the genomic reference strain, none were specific to *sov* mutant chromosomes. In contrast, we found disruptive mutations in [*CG14438*](https://identifiers.org/bioentitylink/FB:FBgn0029899?doi=10.1534/genetics.119.302590) ([Figure 1C](#fig1){ref-type="fig"} and [Table 2](#t2){ref-type="table"}), which encodes an unusually long, 3313-residue protein with 21 C~2~H~2~ ZnFs, multiple nuclear localization sequence (NLS) motifs, and coiled-coil regions ([Figure 1C](#fig1){ref-type="fig"}). The lethal allele *sov^EA42^* has a nonsense mutation (G to A at position 6,764,462) in the [*CG14438*](https://identifiers.org/bioentitylink/FB:FBgn0029899?doi=10.1534/genetics.119.302590) open reading frame that is predicted to truncate the Sov protein before the ZnF domains. The lethal *sov^ML150^* allele has a missense mutation that results in a glutamine to glutamate substitution within a predicted coiled-coil domain (C to G at position 6,763,888). While this is a conservative substitution and glutamate residues are common in coiled-coil domains, glutamine to glutamate substitutions can be disruptive as seen in the coiled-coil region of the σ transcription factor ([@bib36]). We found a frameshift insertion (T at position 6,769,742) located toward the end of [*CG14438*](https://identifiers.org/bioentitylink/FB:FBgn0029899?doi=10.1534/genetics.119.302590) in the female-sterile allele *sov^2^* that encodes 30 novel residues followed by a stop codon within the C-terminal ZnF and removes a predicted terminal NLS. Two *P*-element insertions in the promoter region are weaker female-sterile alleles. Although the locus was named for the female sterility phenotypes of partial loss-of-function alleles, such as *sov^2^*, the phenotype of the more severely disrupted *sov^ML150^*, *sov^EA42^*, and *Df(1)sov* mutations is lethality ([Table 1](#t1){ref-type="table"}). We conclude that [*CG14438*](https://identifiers.org/bioentitylink/FB:FBgn0029899?doi=10.1534/genetics.119.302590) encodes *sov* and is an essential gene.

###### Allele-specific *sov* sequences

  Allele           Lesion location   Location relative to first TSS   Change                   Codon change
  ---------------- ----------------- -------------------------------- ------------------------ --------------
  *sov^NP6070^*    6757638           1,316                            Deletion and insertion   None
  *sov^KG00226^*   6759438           3,116                            Insertion                None
  *sov^ML150^*     6763888           7,566                            C \> G                   Gln1246Glu
  *sov^EA42^*      6764462           8,140                            G \> A                   Trp1437Stop
  *sov^2^*         6769742           13,420                           Insert T                 Frameshift
  *Df(1)sov*       6756569-6770708   ---                              Deletion                 Deletes ORF

*sov* transcript expression and Sov protein localization {#s12}
--------------------------------------------------------

To determine where *sov* is expressed and if it encodes multiple isoforms, we analyzed its expression in adult tissues by RNA-Seq. We noted that while *sov* employs two promoters and two transcription start sites, *sov* transcripts are broadly expressed in multiple tissues as a single messenger RNA (mRNA) isoform with highest expression in ovaries ([Figure 2A](#fig2){ref-type="fig"}). The modENCODE ([@bib33]; [@bib10]) and FlyAtlas ([@bib75]; [@bib49]) reference sets show similar enrichments in the ovaries and early embryos due to maternal deposition. These expression patterns suggest that *sov* is required broadly, but is particularly important for the ovary.

![Sov is widely expressed and localizes to the soma and germline during oogenesis. (A) RNA expression tracks by tissue type from female (red) or male (blue) adults. (B) Cartoon of *Drosophila* egg chamber development showing germarium regions I--III and young egg chamber with cell types labeled. (C) Western blot analysis of WT (genotype: *y*^1^*w*^67c23^) and *GFP-sov* ovarian lysates probed for expression of tagged Sov protein using anti-FLAG and anti-GFP antibodies. βTub antibodies were used as a loading control. A specific band of ∼450 kDa is detected in *GFP-sov* extracts, corresponding to the predicted 446.6-kDa molecular weight of 3xFLAG-GFP-Sov. (D--F') One-day-post eclosion WT germaria, visualized for GFP-Sov (green). All images show single optical sections and anterior is to the left. Dashed boxes highlight inset regions, magnified below. GFP-Sov is enriched in germarium region I (dashed line) with high expression in GSCs (arrows). (D) Sov contrasted with anti-αSpec to label spectrosomes (magenta) and anti-Vas to label germline (red). (E) Sov contrasted with anti-αSpec to label spectrosomes (red) and anti-Tj to label the soma (magenta). (F) Open arrowheads highlight localization of Sov within follicle cell nuclei outlined with WGA. (F') Sov localizes within nurse cell and follicle cell nuclei in mature egg chambers. Bars, 10 μm, insets 5 μm. GSC, germline stem cell; reprod., reproductive; αSpec, αSpectrin; Tj, Traffic jam; Tub, Tubulin; Vas, Vasa; WGA, wheat germ agglutinin; WT, wild-type.](877f2){#fig2}

Given the ovarian enrichment of *sov* RNA, we examined the distribution of Sov protein in developing egg chambers ([Figure 2B](#fig2){ref-type="fig"}). For these studies, we employed our genetically functional *GFP-sov* transgene, which contains ∼3 kb of upstream and downstream regulatory sequences ([Table 1](#t1){ref-type="table"}; see *Materials and Methods*). The *GFP-sov* fusion contains multiple N-terminal tags, including FLAG and sfGFP, and it has a predicted molecular weight of ∼450 kDa. Using two different antibodies, we assayed ovarian extracts by western blot and confirmed that *GFP-sov* generates a protein product of the expected molecular size ([Figure 2C](#fig2){ref-type="fig"}). This protein product is specific to *GFP-sov* lysates, as it is missing in wild-type controls.

Using GFP antibodies to monitor the localization of Sov together with antibodies recognizing Vasa to label the germline, we observed nuclear localization of Sov surrounded by perinuclear Vasa in the germline cells within region 1 of the germarium (dashed line, [Figure 2D](#fig2){ref-type="fig"} and insets), with the highest levels evident within the germline stem cells (GSCs) (arrows; [Figure 2, D--F](#fig2){ref-type="fig"}). Compared to region 1, levels of Sov appear diminished in other regions of the germarium. Nonetheless, we noted nuclear enrichment of Sov in several Tj-positive cells, including follicle stem cells ([Figure 2E](#fig2){ref-type="fig"}, insets). We confirmed nuclear localization of Sov by using fluorescently conjugated WGA to label the nuclear envelope, where Sov was found within follicle cells and follicle stem cell nuclei (arrowheads, [Figure 2, F and F](#fig2){ref-type="fig"}'). In addition, we noted that Sov localized within the nuclei of nurse cells and follicle cells in later-stage egg chambers ([Figure 2F](#fig2){ref-type="fig"}'). These data indicate that Sov localizes to the nucleus in both germline and somatic cells.

*sov* is required in the soma and germline for oogenesis {#s13}
--------------------------------------------------------

Prior characterization of *sov* described pleiotropic female sterility phenotypes, including the complete absence of one or more ovaries, ovarian tumors of germ cells undergoing complete cytokinesis, egg chambers with \> 16 nuclei, arrested egg chamber development in vitellogenic stages, and egg chamber degeneration ([@bib88]). We revisited the phenotypic profile of *sov* by examining transheterozygous females of *sov^2^* with classic and new *sov* alleles ([Figure 3](#fig3){ref-type="fig"}). While we recapitulated the female sterility phenotypes, we note these phenotypes are variable within individuals. For example, a female could be missing one ovary, with the contralateral ovary showing any combination of the egg chamber phenotypes. This variability extended to within-brood effects. For example, *sov* females eclosing first (from mothers allowed 48 hr to lay eggs) showed a weaker phenotype relative to those eclosing on subsequent days. In addition, females eclosing later in the brood showed frequent partial tergite deletions.

![Sov permits normal oogenesis. (A--E) Maximum-intensity projections of germaria (0--2 day posteclosion) stained with anti-Vas (green), anti-Tj (magenta), αSpec (red), and DAPI (blue) in the noted genotypes, with excess dot spectrosomes (arrows) and empty ovarioles (asterisks) shown. (F--I) Quantification of ovarian differentiation phenotypes. *sov^2^* represents the paternal allele in all genotypes. (F and H) Quantification of the number of dot spectrosomes per germarium from 0 to 2- or 5 to 6-day post eclosion females, respectively. (G and I) Quantification of the number of developing egg chambers per ovariole in 0--2- or 5--6-day post eclosion females, respectively. For quantification of dot spectrosomes within 0--2-day germaria, *N* = 28 *sov^2^*/+, *N* = 35 *sov^2^*/*sov^NP6070^*, *N* = 55 *sov^2^*/*sov^EA42^*, *N* = 80 *sov^2^*/*sov^ML150^*, and *N* = 136 *sov^2^*/*Df(1)sov*. For quantification of the number of egg chambers within 0--2-day ovarioles, *N* = 26 *sov^2^*/+, *N* = 35 *sov^2^*/*sov^NP6070^*, *N* = 55 *sov^2^*/*sov^EA42^*, *N* = 76 *sov^2^*/*sov^ML150^*, and *N* = 138 *sov^2^*/*Df(1)sov*. For quantification of dot spectrosomes within 5--6-day germaria, *N* = 51 *sov^2^*/+, *N* = 37 *sov^2^*/*sov^NP6070^*, *N* = 36 *sov^2^*/*sov^EA42^*, *N* = 64 *sov^2^*/*sov^ML150^*, and *N* = 189 *sov^2^*/*Df(1)sov*. For quantification of the number of egg chambers within 5--6 day ovarioles, *N* = 41 *sov^2^*/+, *N* = 27 *sov^2^*/*sov^NP6070^*, *N* = 36 *sov^2^*/*sov^EA42^*, *N* = 62 *sov^2^*/*sov^ML150^*, and *N* = 189 *sov^2^*/*Df(1)sov*. Data shown are from a single representative experiment, and the experiment was repeated twice with similar results. Bars, 10 μm. αSpec, αSpectrin; Tj, Traffic jam; Vas, Vasa.](877f3){#fig3}

To examine the phenotypic consequences of *sov* depletion in greater detail, we focused our analysis on the germarium, where *sov* expression is particularly strong ([Figure 2](#fig2){ref-type="fig"}). The germaria of heterozygous *sov* females appear normal ([Figure 3A](#fig3){ref-type="fig"}). Similarly, germaria from *sov^2^/sov^NP6070^* females show no gross morphological defects ([Figure 3B](#fig3){ref-type="fig"}). In contrast, *sov^EA42^*, *sov^ML150^*, and *Df(1)sov* mutants often show an ovarian tumor phenotype, with a greater than expected number of germ cells with dot spectrosomes (arrows, [Figure 3, C--E](#fig3){ref-type="fig"}), the cytoskeletal organelle normally associates with GSCs and their early cystoblast daughters ([@bib23]). The ovaries from *sov^ML150^* and *Df(1)sov* mutants consisted of degenerate tissue characterized by small, nub-like ovaries comprising dysmorphic germaria ([Figure 3D](#fig3){ref-type="fig"}), ovarian tumors, and empty ovarioles (asterisks, [Figure 3E](#fig3){ref-type="fig"}). To assay the incidence of ovarian stem cell-like tumors, we quantified the number of dot spectrosomes within *sov* germaria using αSpec antibodies ([@bib29]). Normally, germaria contain one dot spectrosome in each of the two or three GSCs ([Figure 2B](#fig2){ref-type="fig"}). Germaria from *sov^2^*/+ and *sov^2^/sov^NP6070^* females contain the expected number of dot spectrosomes ([Figure 3F](#fig3){ref-type="fig"}). In contrast, a significant proportion of germaria from *sov^EA42^*, *sov^ML150^*, and *Df(1)sov* mutants contained at least six dot spectrosomes ([Figure 3F](#fig3){ref-type="fig"}). Similarly, strong *sov* alleles were associated with a reduction in the number of developing egg chambers within a given ovariole ([Figure 3G](#fig3){ref-type="fig"}). For example, the null allele *Df(1)sov* produced degenerate ovarian tissue consisting largely of empty ovarioles ([Figure 3E](#fig3){ref-type="fig"}, asterisks and [Figure 3G](#fig3){ref-type="fig"}). Similar results were observed in germaria from 5--6-day-old females ([Figure 3, H and I](#fig3){ref-type="fig"}). These findings are consistent with GSC or cystoblast hyperproliferation, and/or failed differentiation.

Previous work suggested that *sov* activity is solely required in the soma to permit germline development ([@bib88]). To examine cell type-specific requirements for *sov*, we used [*tj*](https://identifiers.org/bioentitylink/FB:FBgn0000964?doi=10.1534/genetics.119.302590)*-GAL4* to knock down *sov* using the upstream activation sequence short hairpin *P{TRiP.HMC04875}* ([Figure 1C](#fig1){ref-type="fig"}) construct (*sov^RNAi^*) or *mCherry^RNAi^* controls in somatic escort and follicle cells, or *nanos-GAL4* ([*nos*](https://identifiers.org/bioentitylink/FB:FBgn0002962?doi=10.1534/genetics.119.302590)*-GAL4*) for RNA interference (RNAi) in the germline. Relative to the controls, the *tj \> sov^RNAi^* germaria ([Figure 4, A and B](#fig4){ref-type="fig"}) were abnormal, showing ovarian tumor phenotypes similar to *sov* mutants. Germaria were often filled with germline cells with dot spectrosomes (arrows, [Figure 4B](#fig4){ref-type="fig"}) and the follicle cells encroached anteriorly. Similar results were also observed using other somatic drivers (*[c587](http://flybase.org/reports/FBti0037960)-GAL4* and *[da](http://flybase.org/reports/FBgn0267821)-GAL4*). This demonstrates a clear somatic requirement for Sov. Interestingly, germline knockdown via *nos*\>*sov^RNAi^* permitted the production of egg chambers representing all 14 morphological stages of oogenesis, which appeared phenotypically normal (data not shown); however, eggs from these females did not develop, suggesting that *sov* expression in the germline is required maternally to support embryogenesis.

![Sov is required in the germline and soma. Immunofluorescence for the indicated probes in the noted genotypes. (A and B) Single optical sections of control (*mCherry*^RNAi^) and *sov*^RNAi^ expressed in germaria (4--5 days post eclosion) using *tj* \> GAL4 and stained with anti-Vas (blue), -Tj (green), -αSpec (red), and DAPI (white) with dot spectrosomes (arrows). (C) Cartoon of dominant female-sterile germline clonal analysis technique. Recombination occurs between homologs at FRT sequences only in the presence of HS-induced FLP expression ([@bib15]). (D) Quantification of vitellogenic egg production from *sov* germline mutant clones. HS was used (+) to induce expression of FLP, but was omitted (--, no HS) in controls. (E--G) Maximum intensity projections of egg chambers (1 day posteclosion) stained with anti-Orb (green), phalloidin (red), and DAPI (blue). Orb+ cells shown (\*). Bars, (A--D) 20 μm, (G--I) 10 μm. HS, heat shock; RNAi, RNA interference; αSpec, αSpectrin; Tj, Traffic jam; Vas, Vasa.](877f4){#fig4}

Our results showing that germline knockdown of *sov* results in maternal-effect lethality contradict prior work reporting the production of viable embryos from *sov* germline clones ([@bib88]). However, in that study, only the weaker *sov* alleles were examined. To reassess *sov* function in the female germline, we performed germline clonal analysis to assay the production of vitellogenic egg chambers in dissected ovaries ([Figure 4C](#fig4){ref-type="fig"}, see *Materials and Methods*) across an allelic series of *sov* mutations. In the absence of heat-shock/clone induction (negative control), none of the *sov/ovo*^*D1*^ genotypes resulted in clones giving rise to eggs. In the positive control, we observed germline clones of *sov^+^* following heat-shock induction of mitotic clones in *sov*^+^*/ovo*^*D1*^. Clones of the weak *sov^2^* allele yielded eggs that developed into viable progeny, in agreement with previous work ([@bib88]). In contrast, germline clones of the strong *sov* alleles *sov^EA42^* and *Df(1)sov* failed to produce vitellogenic egg chambers or mature eggs ([Figure 4D](#fig4){ref-type="fig"}). The failure to recover *sov^EA42^* and *Df(1)sov* germline clones was not due to spontaneous lethal or female-sterile mutations. Alleles were backcrossed and/or selected for viability in the presence of *Dp(1:3)DC486*, and subsequently maintained as attached-X stocks once the alleles were recombined with FRT sites. Most importantly, we did recover *sov^EA42^* and *Df(1)sov* germline clones in the presence of the rescuing *Dp(1:3)DC486* duplication (data not shown). These data indicate that *sov* is required for germline development into the vitellogenic stages and imply that the apparent strict somatic dependence of *sov* observed by [@bib88] was likely the result of using weak female-sterile alleles in their analysis, which we also observed in the recovery of *sov^2^* germline clones. The *sov* germline phenotype in the clonal analysis was also more extreme than the germline RNAi phenotype, suggesting that our RNAi experiments only partially reduced *sov* expression. Taken together, our data support a role for Sov in both the germline and the soma, consistent with recent reports ([@bib40]).

While many of the sov phenotypes result in aberrant germline development, we also observed what appeared to be defective follicle encapsulation of germline cysts following *sov* depletion. To examine this more closely, we used the oocyte-specific expression of Oo18 RNA-binding protein (Orb) ([@bib48]) to count the number of oocytes per cyst. Orb specifies the future single oocyte at the posterior of the egg chamber in control egg chambers ([Figure 4E](#fig4){ref-type="fig"}). Somatic depletion of *sov* resulted in examples of egg chambers with either too many oocytes ([Figure 4F](#fig4){ref-type="fig"}) or no oocytes ([Figure 4G](#fig4){ref-type="fig"}). In a wild-type 16-cell germline cyst, one of the two cells that has four ring canals becomes the oocyte, and this feature was used to determine if extra germline divisions had occurred in cysts or if multiple cysts were enveloped by the follicle cells. We saw that the egg chambers with multiple Orb+ cells always had \> 16 germ cells, and in the representative example shown all three Orb+ cells had four ring canals, indicating that egg chamber fusion had occurred ([Figure 4F](#fig4){ref-type="fig"}). We conclude that defective follicle encapsulation contributes, in part, to the irregular morphology and abortive development of *sov* mutants.

Sov represses gene expression in the ovary {#s14}
------------------------------------------

Our data show that Sov localizes to the nucleus and is required for oogenesis. To test if *sov* regulates gene expression, we performed transcriptome profiling using triplicated PolyA^+^ RNA-Seq analyses of ovaries from *sov* mutant females, females with ovary-specific knockdown of *sov* using *sov^RNAi^*, and several control females (17 genotypes, 50 samples in total, see *Materials and Methods*). The gene expression profiles of ovaries from sterile females were markedly different from controls, primarily due to derepression in the mutants ([Figure 5A](#fig5){ref-type="fig"}). Differential gene expression was strikingly asymmetric, as genes were overexpressed in *sov* mutants and *sov* knockdowns generated with a variety of GAL4 drivers more often than they were downregulated.

![*sov* functions as a repressor of gene expression. (A) Heatmap of all expressed genes in all genotypes assessed in this study. *k*-means cluster analysis (*k* = 5) was performed on gene RPKMs. The black bar demarks sterile *vs.* fertile phenotypes. (B) Heatmap of differentially expressed genes in *sov* mutants. *k*-means cluster analysis (*k* = 5) was performed on genes and clustered into groups 1--5. Group 1 (dotted box) represents genes that were derepressed in *sov* mutants and somatic knockdown of *sov*. Group 2 (solid box) represents genes that were derepressed in *sov* mutants and germline knockdown of *sov*. Values are mean-subtracted ratios scaled across genotypes (red = higher and blue = lower). Groups 3 and 4 represent genes showing allele-specific derepression. Group 5 shows genes that were repressed in *sov* mutants. The black bar demarks sterile *vs.* fertile phenotypes. (C) Tissue-biased expression in wild-type tissues for genes derepressed in *sov* mutant ovaries. Heatmap from mean-subtracted ratios scaled across tissues (red = higher and blue = lower). RPKM, reads per kilobase per million reads; NRC FC, normalized read count fold change.](877f5){#fig5}

To robustly identify which genes are repressed by Sov^+^, we used replicated samples from all females with three mutant genotypes (*sov^EA42^*/*sov^2^*, *sov^ML150^*/*sov^2^*, and *Df(1)sov*/*sov^2^*) using the different homozygous and heterozygous genotypes in a nested analysis, and calculated a locus-level change in gene expression. There were 6091 genes expressed at significantly different levels in *sov* mutant ovaries relative to the heterozygous controls \[false discover rate (FDR) *p*adj \< 0.05\]. Due to the large number of differentially expressed genes, we reduced the number of genes in our analysis using a highly conservative fourfold differential expression cut off. Among genes showing differences in expression (FDR *p*adj \< 0.05) in this nested analysis, we found 1661 genes with more than fourfold increased expression in mutants, while there were only 172 genes with more than fourfold decreased expression (Table S2).

To determine what types of genes are differentially expressed in *sov* mutants, we performed a *k*-means cluster analysis (genes and genotypes) on this subset of 1833 genes (1,661 + 172) and 17 genotypes to generate five groups of genes, and neatly split sterile and fertile genotypes ([Figure 5B](#fig5){ref-type="fig"}). We also performed GO term analysis ([@bib3]; [@bib61]; [@bib82]) ([Table 3](#t3){ref-type="table"}). As the largest cluster, group 1 contained genes that were derepressed in *sov* mutants and with somatic *sov* RNAi ([Figure 5B](#fig5){ref-type="fig"}, dotted line). GO terms of group 1 genes were enriched for cell signaling, including neuronal communication ([Table 3](#t3){ref-type="table"}, shown in bold), and thus might represent a somatic-specific function of *sov* to repress inappropriate signaling pathways detrimental to somatic--germline communication. Similar upregulation of neuronal genes was previously described in the ovary following loss of other transcriptional repressors ([@bib79]). Group 2 contained a small subset of genes that seemed to be selectively derepressed with germline knockdown of *sov* ([Figure 5B](#fig5){ref-type="fig"}, solid line), based on RNAi driven by *nos*-GAL4. Groups 3 and 4 highlight genes that are significantly derepressed in *sov* mutants; however, the magnitude of derepression seems to be allele-specific, suggesting that differences in the genetic background may also contribute to these gene expression changes ([Figure 5B](#fig5){ref-type="fig"}). There was no significant GO term enrichment in groups 2--4. Group 5 represents genes with decreased expression in *sov* mutants ([Figure 5B](#fig5){ref-type="fig"}). This group contained only a few significant GO terms that were predominantly oogenic in nature, as expected given the general lack of mature eggs. For example, there was poor expression of the chorion genes that are required to build the eggshell ([@bib67]).

###### GO term enrichment analysis of derepressed genes in *sov* mutants

  Enriched GO terms                                        Fold enrichment   *P*-value
  -------------------------------------------------------- ----------------- --------------
  Neuromuscular synaptic transmission (GO:0007274)         4.29              1.61E-02
  **Synaptic transmission (GO:0007268)**                   **3.42**          **1.83E-12**
  Neuron--neuron synaptic transmission (GO:0007270)        3.24              3.17E-03
  Cyclic nucleotide metabolic process (GO:0009187)         3.16              6.46E-03
  **Cell--cell signaling (GO:0007267)**                    **3.16**          **1.48E-12**
  **System process (GO:0003008)**                          **2.27**          **2.35E-13**
  **Single-multicellular organism process (GO:0044707)**   **2.15**          **2.23E-14**
  **Multicellular organismal process (GO:0032501)**        **2.1**           **8.09E-14**
  Neurological system process (GO:0050877)                 2.08              5.49E-09
  Cell surface receptor signaling pathway (GO:0007166)     1.82              6.25E-03
  Cell communication (GO:0007154)                          1.71              6.31E-08
  Signal transduction (GO:0007165)                         1.64              4.65E-05

Enriched GO terms in *sov* mutants. Terms in bold are significantly enriched GO terms from genes within group 1 cluster analysis ([Figure 5B](#fig5){ref-type="fig"}). GO, gene ontology.

It is formally possible that mRNAs expressed in wild-type late-stage egg chambers in our RNA-Seq analysis could skew the differential expression analysis in comparison to *sov* mutant ovaries, which lack these stages. To address this concern, we calculated the log2 fold change values of genes that are considered to have high (1980 genes) or very high (742 genes) expression in 0--2-hr-old embryos according to FlyBase RNA-Seq expression profiles (Table S3) ([@bib33]). Genes in the high and very high categories had a mean log2 fold change of −0.14 and −0.23, respectively, in *sov* mutant ovaries. Conservatively correcting the log2 fold change values of all genes in our analysis by subtracting the very high category's −0.23 log2 fold change resulted in 1512 genes with more than fourfold increased expression in mutants and 199 genes with more than fourfold decreased expression. Thus, this correction resulted in only a minor effect on the trend we identified. We also removed the genes with high expression in 0--2-hr-old embryos and recalculated differential expression. Again, this had no overt effect on the outcome. We observed 1625 or 1590 genes with increased expression in *sov* mutants even with the very high or high genes removed, respectively. We conclude that the differences in gene expression observed in *sov* mutants are not due to the absence of advanced oogenic stages. Rather, our expression analyses are most consistent with a role for Sov in the widespread repression of gene expression.

Our gene expression analysis showcases the aberrant derepression genes in response to *sov* loss. To explore where these derepressed genes are normally expressed, we examined their expression in other female tissues and in testes in a set of quadruplicated RNA-Seq experiments in wild-type flies ([Figure 5C](#fig5){ref-type="fig"}). Many of the genes derepressed in *sov* mutant ovaries were highly expressed in other tissues. Notably, we found that these depressed genes were largely uncharacteristic of ovary or testes expression, and were more similar to that of head and thorax tissue expression. We conclude that *sov* functions broadly to repress gene expression, preventing the misexpression of genes normally expressed elsewhere.

Comparison to previous HP1a expression data in ovaries {#s15}
------------------------------------------------------

The repressive role of *sov* might require other chromatin-associated factors that also repress gene expression in the ovary. We compared our RNA-Seq data to data generated from germline knockdown of *HP1a*, *SETDB1*, and *WDE* in a common pipeline and we found limited overlap (Table S4). When germ cells have a male identity in a female soma, this results in ovarian tumors ([@bib66]; [@bib64]). The dot spectrosome phenotype in *sov* ovaries could be due to sex transformation. In addition to a general role, it has been suggested that heterochromatin factors might play a critical role in determining germline sexual identity ([@bib97]). SETDB1 has been reported to silence the male-determining *[phf7](http://flybase.org/reports/FBgn0031091)* gene to allow for female germline sexual identity. Therefore, we specifically asked if *sov* alters *phf7* expression, both overall and at the level of sex-specific promoter choice. Loss of *sov* was associated with modestly altered expression of *phf7* (*sov* mutants: *p*adj = 0.02 and log2 fold change = --0.21, and *sov* germline RNAi: *p*adj = 0.98 and log2 fold change = 0.08), but *sov* was not required for male-specific promoter repression ([Figure 5D](#fig5){ref-type="fig"}). Taken together, these data do not support a role for *sov* in germline sex determination, but they do support the importance of *sov* as a general repressive factor.

Sov represses transposon expression {#s16}
-----------------------------------

Our data strongly support a general role of Sov in regulating gene expression. Recent work described a role for Sov function in the regulation of transposon expression ([@bib22]). Indeed, our RNA-Seq analysis identified a dramatic and coherent elevation of transposon expression in all *sov* mutant genotypes; no cases of underexpression were observed ([Figure 6A](#fig6){ref-type="fig"} and Table S2). For example, when we used the weak female-sterile *sov^2^* allele *in trans* to strong alleles (*sov^EA42^/sov^2^*, *sov^ML150^/sov^2^*, and *Df(1)sov/sov^2^*), 117 out of 138 transposable elements were expressed at significantly higher levels (FDR *p*adj \< 0.05). Using the same conservative fourfold cutoff as before, we found that 91 transposable elements had more than fourfold increased expression (FDR *p*adj \< 0.05) in *sov* mutants, while none had more than fourfold decreased expression. These data confirm that Sov is required to suppress transposon expression.

![Transposon expression in *sov* mutants. (A) Number of transposons with a greater (red) or less than (blue) fourfold change in gene expression (FDR *p*adj value \< 0.05) in *sov* mutants or RNAi knockdown when compared to controls. (B) Transposable element expression in *sov* mutants (sterile) and controls (fertile). Heatmap from mean-subtracted reads (in RPKM; red = higher and blue = lower) scaled for each transposable element (rows) across genotypes (columns). The black bar demarks sterile *vs.* fertile phenotypes. Transposon classes for DNA, non-LTR (Jockey), telomeric repeat (dashed box), and LTR (Gypsy, Copia, and PAO) are indicated. FDR, false discovery rate; rel. relative; RNAi, RNA interference; RPKM, reads per kilobase per million reads.](877f6){#fig6}

There is tremendous diversity in transposon types in *Drosophila* ([@bib60]). Broadly, there are retrotransposons that utilize reverse transcription and DNA elements, such as *P*-elements, that excise and reinsert. Retrotransposons can be further divided into those with long terminal repeats (LTRs)---such as *Gypsy*, *Copia*, and *PAO*---and those lacking LTRs, such as *Jockey*. While many transposons are considered to be detrimental when active, the non-LTR *HeT-A*, *TAHRE*, and *TART* transposons are the structural basis of *Drosophila* telomeres ([@bib58]). All of these classes of transposable elements were derepressed in *sov* mutants and in flies where *sov^RNAi^* was driven by the ubiquitously expressed *da-GAL4* driver ([Figure 6B](#fig6){ref-type="fig"}). Interestingly, somatic knockdown of *sov* in the cells encasing the germ cells using *c587-GAL4* or [*tj*](https://identifiers.org/bioentitylink/FB:FBgn0000964?doi=10.1534/genetics.119.302590)-GAL4 resulted in derepression of most of the transposon classes, including the *Gypsy* and *Copia* classes, which are *Drosophila* retroviruses that develop in somatic cells and are exported to the developing germline ([@bib94]). Thus, wild-type *sov* may be important to protect the germline from infection.

Germline knockdown of *sov* driven by [*nos*](https://identifiers.org/bioentitylink/FB:FBgn0002962?doi=10.1534/genetics.119.302590)*-GAL4* resulted in significant derepression of 20 transposable elements ([Figure 6B](#fig6){ref-type="fig"} and Table S2). Among these, we found that there was a greater magnitude of derepression of the transposons required for normal telomere function. *HeT-A*, *TAHRE*, and *TART*, which are important for telomere function, had a mean log2 fold change of 7.8 with germline knockdown of *sov*, while the other 17 transposable elements had a mean log2 fold change of 3.9. This indicates that telomere classes of transposons were more sensitive to loss of *sov* than other classes of transposons in the germline. These results are strikingly similar to the derepression of telomere transposons following germline-specific knockdown of HP1a ([@bib81]). Comparative analysis between our data set and RNA-Seq reported for *HP1a*, *SETDB1*, or *WDE* ([@bib97]) highlights overlapping derepression of *HeT-A* and several other transposons (Table S4). These findings suggest that the general role of *sov* in silencing transposon expression includes both transposons necessary for normal cellular functions, exemplified by the telomeric transposons, and transposons with no known beneficial cellular roles. Taken together, our RNA-Seq analyses define Sov as a negative regulator of gene expression, of which transposons represent one class of Sov targets.

Sov is a suppressor of PEV {#s17}
--------------------------

The ovary may be particularly susceptible to heterochromatin defects, as mutations in several members of the HP1a complex result in female sterility ([@bib18], [@bib19]; [@bib93]; [@bib81]). Loss of the H3K9 methyltransferase SETDB1/[*egg*](https://identifiers.org/bioentitylink/FB:FBgn0086908?doi=10.1534/genetics.119.302590) ([@bib18], [@bib19]; [@bib86]) or the H3K4 demethylase encoded by *lysine-specific demethylase 1* ([LSD1](http://flybase.org/reports/FBgn0260397)) ([@bib24]; [@bib76]; [@bib28], [@bib29]) results in degenerate phenotypes in the ovary, yet these factors function widely to regulate gene expression. We reasoned that Sov may similarly function to regulate gene expression outside of the ovary.

HP1a was first characterized in *Drosophila* as a suppressor of PEV ([@bib17]). To test the hypothesis that *sov* negatively regulates gene expression by promoting heterochromatin formation, we examined the effects of *sov* mutations on PEV in the eye, where patches of *w^+^* (red pigmented) and *w^--^* (unpigmented) eye facets are easily observed ([Figure 7A](#fig7){ref-type="fig"}). If, like HP1a, Sov represses gene expression by promoting heterochromatin formation ([@bib26]), then *sov* mutations should suppress PEV, which is scored as increased eye pigmentation. We obtained five variegating *w^+^* transgene insertions associated with either the heterochromatic pericentric region of chromosome arm 2L or spread along the length of heterochromatin-rich chromosome 4. In control animals, these insertions show characteristic eye variegation patterns ([Figure 7B](#fig7){ref-type="fig"}). Consistent with the allelic strengths seen in previous experiments, the weak female-sterile *sov^2^* allele did not suppress PEV ([Figure 7C](#fig7){ref-type="fig"}), but the stronger lethal mutations *sov^ML150^*, *sov^EA42^*, and *Df(1)sov* dominantly suppressed PEV ([Figure 7, D--F](#fig7){ref-type="fig"}). These data establish a role for Sov in heterochromatin function and demonstrate that Sov is capable of regulating gene expression outside of oogenic contexts.

![Sov is a dominant suppressor of position-effect variegation. (A) Cartoon of position-effect variegation in the eye. Expression of the [*white*](https://identifiers.org/bioentitylink/FB:FBgn0003996?doi=10.1534/genetics.119.302590) gene (bent arrow, thick bar, red) can be silenced (white) by proximal heterochromatin (squiggled) spreading. (B--F) Eyes from adults of the indicated genotypes (columns) with variegated expression of *P{hsp26-pt-T}* transgenes inserted into the indicated chromosomal positions (rows).](877f7){#fig7}

Sov colocalizes with HP1a during heterochromatin formation {#s18}
----------------------------------------------------------

Our loss-of-function studies allow us to draw several parallels between Sov and the core heterochromatin factor HP1a. Both proteins localize to the nucleus, are required to suppress transposons, and function more broadly as general repressors of gene expression. Moreover, recent work in *Drosophila* S2 cells suggests that Sov complexes with HP1a ([@bib1]), hinting that Sov and HP1a may coordinate the functions of heterochromatin.

To determine if Sov colocalizes with HP1a in the nucleus, we examined HP1a-RFP and GFP-Sov localization in 1--2-hr-old live embryos. During *Drosophila* embryogenesis, nuclei undergo rapid synchronous nuclear divisions prior to cellularization at cleavage division/nuclear cycle (NC) 14 ([@bib31]). HP1a and Sov colocalized in the nuclei of all NC 10--12 embryos examined, including those that were monitored and quantified by live imaging ([Figure 8A](#fig8){ref-type="fig"}; *N* = 7 embryos). During interphase, prophase, and nuclear envelope breakdown, both HP1a and Sov were nuclear ([Figure 8A](#fig8){ref-type="fig"}). In prophase, HP1a and Sov colocalized, and were enriched in regions of condensed DNA ([Figure 8A](#fig8){ref-type="fig"}, 4:30). Whereas low levels of HP1a decorated DNA throughout nuclear division, Sov was depleted during mitosis ([Figure 8A](#fig8){ref-type="fig"}, 10:00 and 11:10). However, upon reentry into interphase, Sov localization to nuclei resumed and was coincident with HP1a ([Figure 8A](#fig8){ref-type="fig"}, 14:30).

![Sov colocalizes with HP1a. Stills from live imaging of embryos expressing GFP-Sov and RFP-HP1a. (A) Localization of GFP-Sov and RFP-HP1a (rows) in an embryo progressing from NC 10 to 11, with cell cycle stages (columns) and time (min:sec) shown. (B) NC 14 embryo. Boxed regions are magnified in insets below. An HP1a subnuclear domain is shown (arrows). (B') Single optical section containing peak HP1a fluorescence of inset from (B). Dashed line indicates region used for histogram analysis. (A and B) Images show maximum projections through 1.5-μm volume and were captured at 1F/30 sec. Bar, 10 μm; insets, 5 μm. (C) Histogram of HP1a and Sov fluorescence intensity measured in (B'). Fluorescence levels (arbitrary units) normalized to the peak fluorescence intensity for each channel and the distance (μm) to peak HP1a signal. Half-maximum HP1a fluorescence is shaded (yellow). a.u., arbitrary units; NC, nuclear cycle; NEB, nuclear envelope breakdown; RFP, red fluorescent protein.](877f8){#fig8}

Formation of heterochromatin is contemporaneous with or slightly proceeds HP1a apical subnuclear localization in NC 14 ([@bib76]; [@bib95]). At this stage, we observed a strong colocalization of HP1a and Sov. Measuring the distribution of HP1a and Sov ([Figure 8, B and B](#fig8){ref-type="fig"}') revealed high levels of colocalization within HP1a subnuclear domains ([Figure 8C](#fig8){ref-type="fig"}, shaded region). These data support the idea that HP1a and Sov assemble into a complex in the nucleus. Moreover, our live imaging reveals that Sov localizes to HP1a-positive foci around the time heterochromatin first forms. These findings support the possibility that Sov functionally coordinates heterochromatin stabilization and/or maintenance together with HP1a.

Discussion {#s19}
==========

Sov is a novel heterochromatin-associated protein {#s20}
-------------------------------------------------

Gene repression is often stable over extended timescales. Emerging themes suggest that multiple members of protein complexes, rather than a single key component, maintain a stabilized chromatin state. For example, complexes formed by proteins of the repressive Polycomb group (PcG) provide a repressive epigenetic memory function ([@bib44]). To create a stable epigenetic state, PcG complexes have subunits that modify histones and bind these modifications ([Figure 9A](#fig9){ref-type="fig"}). Chromatin binding of PcG complexes also involves DNA-binding proteins, such as the YY1-like ZnF protein Pleiohomeotic (Pho), which further reinforce localization ([@bib11]). The DNA-anchoring proteins within PcG complexes are at least partially redundant with the histone-binding components ([@bib11]), suggesting that localization is robust due to multiple independent localization mechanisms. Such partially redundant components functionally contribute to stable gene repression.

![Working model of *sov* function. (A) Polycomb complexes (Pc) in flies and (B) Krüppel associated box (KRAB) complexes in mammals use a DNA-binding protein (Pho and KRAB; green) that binds sequence motifs in addition to histone code readers (Pc and HP1a; yellow), which bind to modified histones (red). These complexes also bear enzymes that create the histone marks \[E(z) and Egg or SETDB1; black\]. They have other proteins as well (such as KAP-1; orange). Like KRAB proteins, Sov is in complex with HP1a (yellow). We propose that it binds to DNA to provide another mechanism for tethering to chromosomes, in addition to HP1a binding to methylated H3K9. This partially redundant mechanism contributes to the stabilization of a repressed chromatin state.](877f9){#fig9}

The repressive chromatin protein HP1a may coordinate with other repressive proteins ([Figure 9B](#fig9){ref-type="fig"}). The Krüppel associated box (KRAB) family members use the KRAB-Associated Protein (KAP1) adapter protein to associate with HP1a and the SETDB1 methylase that modifies histones to enable HP1a binding. Although KRAB proteins have not been identified in *Drosophila*, the [*bonus*](https://identifiers.org/bioentitylink/FB:FBgn0023097?doi=10.1534/genetics.119.302590) ([*bon*](https://identifiers.org/bioentitylink/FB:FBgn0023097?doi=10.1534/genetics.119.302590)) gene encodes a KAP1 homolog ([@bib5]). *Drosophila* also has a SETDB1 encoded by [*egg*](https://identifiers.org/bioentitylink/FB:FBgn0086908?doi=10.1534/genetics.119.302590), and loss of [*egg*](https://identifiers.org/bioentitylink/FB:FBgn0086908?doi=10.1534/genetics.119.302590) results in ovarian phenotypes reminiscent of those observed in *sov* loss-of-function females ([@bib18], [@bib19]; [@bib86]). The single, very long, and ZnF-rich Sov protein may play a DNA- or RNA-binding role to help tether HP1a to chromatin ([Figure 9C](#fig9){ref-type="fig"}). If Sov uses subsets of fingers to bind sequences, it could localize to many locations. As in the case of Pho in the PcG complexes, Sov might contribute to heterochromatin stability rather than its formation, as we did not observe gross delocalization of HP1a following *sov* knockdown via RNAi, similar to recent findings ([@bib40]). Consistent with this idea, nuclear colocalization of Sov is cell cycle-dependent whereas HP1a decorates DNA within cycling embryos constitutively. Perhaps recruitment of Sov to DNA serves to stabilize HP1a-containing complexes.

Repression by Sov promotes germline differentiation {#s21}
---------------------------------------------------

The ovary may be particularly sensitive to loss of *sov* and other HP1a complex members. For example, the activities of both the H3K9 methyltransferase SETDB1, encoded by [*egg*](https://identifiers.org/bioentitylink/FB:FBgn0086908?doi=10.1534/genetics.119.302590) ([@bib18], [@bib19]; [@bib86]), and the H3K4 demethylase encoded by *LSD1* ([@bib24]; [@bib76]; [@bib28], [@bib29]) are required in the somatic cells of the germarium for GSC maintenance, normal patterns of differentiation, and germline development. Dynamic changes in chromatin landscapes within germline and somatic cells are critical for oogenesis, and contribute to the regulated gene expression required for tissue development ([@bib59]; [@bib79]; [@bib4]; [@bib7]; [@bib69]; [@bib55]). Genome-wide profiling hints at a progression from open chromatin in stem cells to a more closed state during differentiation ([@bib14]). We predict that disrupting this progressive repression in the ovary through loss of *sov* or other heterochromatin factors contributes to stem cell hyperproliferation, and defective oogenesis.

The *sov* female sterility phenotype is complex and somewhat variable, but weak *sov* alleles have more severe consequences in somatic cells than germ cells. Stronger lethal alleles show a germline-dependent block in egg chamber development, based on our failure to recover germline clones of *sov^EA42^* and *Df(1)sov*. We propose that the pleiotropy of *sov* mutations may be attributed to a single mechanism wherein Sov helps control facultative heterochromatin stabilization required to repress ectopic gene expression and tissue-inappropriate responses in the ovary, and elsewhere in the organism. For example, *sov* has a clear impact on PEV in the eye.

Sov represses transposons {#s22}
-------------------------

We observed dramatic derepression of transposons in *sov* mutants. Consistent with our observations, [@bib22] reported a role for *[sov](http://flybase.org/reports/FBgn0286831)* in transposon repression in a genome-wide RNAi screen. That work raised the possibility that transposon repression by Sov occurs via the Piwi-interacting RNA (piRNA) pathway ([@bib8]; [@bib92]; [@bib80]). However, genes involved more strictly with transposable element regulation, such as Piwi, do not have strong dosage effects on PEV ([@bib35]), while *sov* (this study) and *HP1a*/*[Su(var)205](http://flybase.org/reports/FBgn0003607)* do ([@bib38]; [@bib26]; [@bib17]). Furthermore, amorphic *sov* alleles are embryonic lethal, whereas piRNA pathway mutants are viable with maternal-effect lethal phenotypes. These distinctions suggest that Sov has a more general role in heterochromatin, rather than a function restricted to transposon repression. Germline knockdown of HP1a results in a strong derepression of telomeric transposons ([@bib81]), just like that found with germline knockdown of Sov. These key differences between the *sov* and [*piwi*](https://identifiers.org/bioentitylink/FB:FBgn0004872?doi=10.1534/genetics.119.302590) phenotypes imply a general role of *sov* with *HP1a* and heterochromatin, rather than a specific role in the piRNA pathway and oogenesis as recently reported ([@bib40]).

Conclusions {#s23}
-----------

The *sov* locus is required for the same major functions in PEV, viability, transposon repression, and gene repression as the HP1a locus. Further, HP1a and Sov colocalize in the nucleus. These data support the idea that Sov encodes a novel and essential protein that is generally repressive, which may act by stabilizing heterochromatin by facilitating HP1 functions.
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